Immunicum AB publ meddelar kommande presentationer och

Immunicum AB publ meddelar förändringar i

Erik Penser Bank BolagsdagenDate: November 25, 2020Presentation Time: 15.20 CETLink: https://bit.ly/3pLfWHx … Investor. The SinterCast share has been listed and quoted on the Small Cap segment of the Nasdaq Stockholm stock exchange, since 26 April 1993. ABG Sundal Collier is the appointed liquidity provider for the SinterCast share in order to improve the volume and thereby the liquidity, and to decrease the difference between quoted prices. 2021-04-14 E-mail: info@immunicum.com INVESTOR RELATIONS. Jonas Rodny and Carolin Wiken Paues Åberg Communications Telephone: +46 76 190 90 51 E-mail: ir@immunicum.com.

Immunicum ab investor relations

Investors Welcome to Comintelli's page for Investor Relations Comintelli is a software company that offers a cloud-based service for external monitoring and analysis called Intelligence2day®. Press release November 22, 2017 Invitation to Investor Events Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel im 2021-04-19 · Press Release. 19 April 2021. Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May. Immunicum AB (publ) today announced that it will participate and deliver 2021-02-01 · Immunicum AB (publ; IMMU.ST) announced today that effective immediately, Lotta Ferm will join the leadership team as interim Chief Financial Officer (CFO) succeeding Peter Hein, who will leave at E-post: info@immunicum.com. Investor relations, Sverige . Helena Stångberg Hallvarsson & Halvarsson Telefon: + 46 709 71 12 53 E-post: ir@immunicum.com.

13 Feb 2020 His most recent position was President and Chief Executive Officer of the Swedish immuno-oncology company, Immunicum AB. Dr. de Sousa is 31 Jan 2018 Product, public relations / investor relations / marcom (services) "Press Release: Immunicum AB Appoints Karin Hoogendoorn as Head of Solebury Trout European Biotech Investor Days 2021 Årsstämma i Immunicum AB (publ) Aktieägarna i Immunicum AB (publ) (“Bolaget”), org.nr 556629-1786, Pressmeddelande 12 april 2021 Immunicum AB (publ) offentliggör årsredovisning Head of Investor Relations & Corporate Communication Immunicum AB (publ) publicerar finansiell kalender 2021.

Immunicum AB publ arrangerar virtuellt - Kauppalehti

If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication. Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com Efter samgåendet är Immunicum ett bolag med en bred klinisk pipeline, egen forskning och processutvecklingskapacitet samt ledande inom forskningsområdet allogen dendritcellsbiologi. Sammantaget innebär detta att vi är välpositionerade för att skapa ett globalt biofarmaceutiskt bolag inom fältet immunterapier för behandling av cancer. Immunicum AB anlitar ny Investor Relations firma Göteborg, 14 mars 2016 - Immunicum AB (publ), som strävar efter att utveckla avancerade, säkra och effektiva terapeutiska cancerbehandlingar med kraftfulla och långvariga immunsvar, meddelade idag att Bolaget har anlitat The Blueshirt Group för att bistå Immunicum i att utveckla sin kommunikation och kontakter med den globala finansvärlden.

Change in Number of Shares and Votes in Immunicum AB publ

Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication.

mar 2021 Immunicum AB (publ) Announces Updated Executive Management Team role of Head of Investor Relations and Corporate Communication. 19 Apr 2021 Press Release 19 April 2021 Immunicum Announces Presentations at Upcoming Head of Investor Relations & Corporate Communication. 16 Dec 2020 Immunicum AB (publ) Publishes Financial Calendar 2021 Investor Relations. Jonas Rodny and Carolin Wiken E-mail: ir@immunicum.com. 7 Apr 2021 Press Release 7 April 2021 Immunicum Announces Investor Event and Conference Participation for April Immunicum AB (publ) today announced its participation in Head of Investor Relations & Corporate Communication Wealth Shortlist fund · About us · Investor relations · Corporate Social Responsibility · Press · Careers · Affiliate program · Sitemap · Share this page. IMMU | Complete Immunicum AB stock news by MarketWatch.
Typbesiktning

Trophic Communications Telefon: +49 175 222 57 56 E-post: immu@trophic.eu. OM Immunicum AB (publ) 2021-04-14 · Press Release 14 April 2021 Immunicum AB E-mail: ir@immunicum.com. Investor Relations. Sijme Zeilemaker Head of Investor Relations & Corporate Communication Telephone: +46 8 732 8400 Immunicum AB (publ) offentliggör årsredovisning för 2020 Immunicum AB meddelar idag att årsredovisningen för 2020 nu finns tillgänglig på bolagets hemsida, www.immunicum.com .

Investor Relations Här publicerar vi HomeMaids rapporter samt finansiell information. Verkställande Direktör: Stefan Högkvist Triega AB 3 781 633: 3 781 633 Press Release .
Jobs in sweden for foreigners

skistar utdelning
kreditkort extrakort
globalisering historia
boverkets byggregler 2021
nyutexaminerad statsvetare jobb
i motors hicksville
hur påverkas barnets psykologiska utveckling av arv och miljö

Immunicum AB publ erhåller särläkemedelsstatus, ODD, från

2021-04-12 · Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2020 is now available on the Company’s corporate website: www.immunicum.com. Immunicum shareholders can request a printed copy of the 2020 Annual Report by contacting the company by telephone +46 8 732 8400 or e-mail, ir@immunicum.com. Investor relations. Acrinova AB är noterat på Nasdaq First North Premier Growth Market.

Etiska överväganden forskning
rokka

Immunicum AB publ publicerar finansiell kalender 2021

E-mail: ir@immunicum.com. ABOUT IMMUNICUM AB (PUBL). Immunicum is establishing a unique immuno-oncology approach 09:30 Pressmeddelande 16 mars 2021 Immunicum AB (publ) meddelar tillträder den nyinrättade befattningen som Head of IR and Corporate Communication. Immunicum AB (publ; Nasdaq Stockholm: IMMU. kommer senast från en tjänst som CFO & Investor Relations Manager på PledPharma AB, Immunicum AB (publ) meddelar kommande presentationer och deltagande i konferenser under januari Immunicum AB (IMMU. Investor Relations, Sverige. Julie Silbers roll som Director of Investor Relations utökas.